The new UICC classification should be adopted for clinical research. Pre-therapeutic explorations, including high-quality colonoscopy with biopsies of suspicious lesions and endoscopic treatment of accessible synchronous lesions, are recommended. Immunohistochemistry and molecular biology testing for protein extinction and microsatellite instability should be offered to all patients.